SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

 

 

TENDER OFFER STATEMENT

Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 1)

 

 

BlackRock Private Investments Fund

(Name of Subject Company (Issuer))

BlackRock Private Investments Fund

(Names of Filing Person(s) (Issuer))

Common Shares of Beneficial Interest, Par Value $0.001 per Share

(Title of Class of Securities)

Institutional Shares – 09260N105

Class D Shares – 09260N303

Class S Shares – 09260N402

Class T Shares – 09260N501

(CUSIP Number of Class of Securities)

John M. Perlowski

BlackRock Private Investments Fund

50 Hudson Yards

New York, New York 10001

(800) 882-0052

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person(s))

 

 

Copies to:

 

Margery K. Neale, Esq. Jay Spinola, Esq.		Janey Ahn, Esq.
Willkie Farr & Gallagher LLP		BlackRock Advisors, LLC
787 Seventh Avenue		50 Hudson Yards
New York, New York 10019		New York, New York 10001

 

 

July 31, 2026

(Date Tender Offer First Published, Sent or Given to Security Holders)

 

 

 

☐	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which this statement relates:

 

☐

third party tender offer subject to Rule 14d-1

☒

issuer tender offer subject to Rule 13e-4

☐

going-private transaction subject to Rule 13e-3

☐

amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

 

 

This Amendment No. 1 (this “Amendment”) amends and supplements the Issuer Tender Offer Statement on Schedule TO originally filed with the Securities and Exchange Commission (the “SEC”) by BlackRock Private Investments Fund, a Delaware statutory trust (the “Trust”), on July 31, 2026 (the “Schedule TO”) and relates to the Trust’s offer to purchase up to 5% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (including Institutional, Class D, Class S and Class T common shares, collectively, the “Shares”), as of June 30, 2026, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated July 31, 2026 and in the related Letter of Transmittal, copies of which were previously filed as exhibits to the Schedule TO.

This Amendment is being filed solely for the purpose of adding an exhibit to the Schedule TO and to satisfy the requirements of Rule 13e-4(c)(1) under the Exchange Act. This Amendment does not otherwise modify any of the information previously reported on the Schedule TO.

Item 12(a). Exhibits

Item 12 of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(1)(vi) Excerpt from Current Report on Form 8-K, filed on September 11, 2026, is filed herewith.

Item 12(c). Filing Fees

Filing Fee Exhibit is filed herewith.

 

- 2 -

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

- 3 -

Exhibit Index

 

(a)(1)(vi)		Excerpt from Current Report on Form 8-K, filed on September 11, 2026
		Filing Fee Exhibit.

 

- 4 -